Abstract
Since the outbreak of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002, the emergence and expansion of endemic and epidemic coronaviruses has been accelerating on a scale not seen for any other group of viruses with pandemic potential. In the past two decades alone, five new human coronaviruses have been discovered, three of which are highly pathogenic.1,2 The coronavirus disease 2019 (COVID-19) pandemic is just the latest example of the danger posed by zoonotic diseases, foreshadowed by the regional, but unabated, emergence of Middle East respiratory syndrome coronavirus (MERS-CoV).
Highlights
Since the outbreak of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002, the emergence and expansion of endemic and epidemic coronaviruses has been accelerating on a scale not seen for any other group of viruses with pandemic potential
The coronavirus disease 2019 (COVID-19) pandemic is just the latest example of the danger posed by zoonotic diseases, foreshadowed by the regional, but unabated, emergence of Middle East respiratory syndrome coronavirus (MERS-CoV).[3]
In recognition of its intrinsic threat to public health and as a prototypical member of the family Coronaviridae, WHO, in 2015, prioritised MERS-CoV as a pathogen to which increased resources should be dedicated for countermeasure research and development
Summary
Since the outbreak of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002, the emergence and expansion of endemic and epidemic coronaviruses has been accelerating on a scale not seen for any other group of viruses with pandemic potential. While noting that binding antibody levels are reported differently between these studies, a single dose of ChAdOx1 MERS vaccine induced detectable antibody titres at day 180 (in 18 [75%] of 24 participants) and day 364 (13 [68%] of 19 participants) after vaccination, whereas with MVA-MERS-S only three (14%) of 22 vaccine recipients had detectable antibody titres at day 180.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
